1 Under-the-Radar Cannabis Stock to Consider Buying

Harvest Health & Recreation Inc (CNX:HARV) possesses strong roots south of the border. Here’s why the cannabis firm is worth considering.

The marijuana industry continues its inexorable march forward, particularly in the lucrative U.S. market. In late May, Illinois became the latest state to legalize recreational marijuana by passing bill HB 1438. The piece of legislature was officially signed into law in June.

This development is just the latest in an ongoing transformation within the cannabis industry, which will yield billions of dollars in sales in just a few years.

For Canadian investors looking to profit from the U.S. cannabis market, one option to consider is Harvest Health & Recreation Inc (CNX:HARV). 

One of the largest footprints in the U.S.

One reason Harvest could be an attractive proposition is simply its multi-state presence and the number of stores it owns. As of late June, the vertically integrated cannabis company had the rights to about 210 facilities in the U.S., including 135 retail locations, across about 17 states.

While many other firms can boast a multi-state presence comparable to that of Harvest, none possesses the rights to nearly as many facilities. This factor makes Harvest — in its own words — a cannabis company with one of the largest and deepest footprints in the U.S. 

Harvest achieved its current position in the market largely by way of acquisitions. The latest of these — officially approved by the company’s shareholders during a meeting in June — was the acquisition of Verano Holdings Inc. Verano, one of the largest vertically integrated licensed operators of cannabis facilities, gave Harvest the rights to about 200 facilities across 16 states, including 123 dispensaries.

The all-stock transaction was valued at approximately USD$850,000,000. For a little while, this transaction was the largest acquisition in the U.S. cannabis market. 

Another significant acquisition Harvest made this year was its deal to acquire CannaPharmacy, Inc., a vertically integrated company that operates primarily in four eastern states, namely Maryland, Delaware, New Jersey, and Pennsylvania.

These acquisitions have prepared Harvest to handle the rise in demand for cannabis products better than most of its peers. The firm likely has access to more consumers than almost any of its competitors.

But how has Harvest performed so far?

Financial results

Last year, Harvest generated revenues of about USD $47 million, or about CAD $61 million, representing a 105% increase from 2017. The firm also posted a gross profit margin of 57%, although that was down about 3% from 2017.

The company’s net loss of about USD $67 million was a significant drop from its 2017 net profit of $USD $3,591,000. Harvest’s latest reported financial results, Q2 2019, showed that the company is making headway.

Its revenues of USD $26.6 million represented a 29% sequential increase. Further, Harvest is keeping its foot on the pedal as far as its expansion efforts are concerned.

The firm obtained more than $200 million in funding from a private investment firm and has already opened about half a dozen new retail locations in the third quarter. Finally, Harvest recently acquired the right to distribute its CBD products in more than 10,000 retail stores. 

The bottom line

While Harvest possesses the assets to rack up high sales and revenues for many years to come, it’s doubtful whether the company can earn substantial profits.

In particular, its profit margins have been decreasing, and the addition of all the facilities it acquired in its latest M&A will not make it easy to improve efficiency. In short, while it may be wise to keep an eye on the Vancouver-based company, it might not be the right time to pull the trigger just yet. 

Fool contributor Prosper Junior Bakiny has no position in any of the stocks mentioned.

More on Cannabis Stocks

runner checks her biodata on smartwatch
Cannabis Stocks

Average TFSA and RRSP Balances at Age 45: Are You on Par?

Most 45-year-olds have less than $100,000 combined in their TFSA and RRSP. Here's how TerrAscend could help you close the…

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Risky Stocks That Could Send Your $100,000 Investment to $0

Cannabis stocks look risky because price wars, dilution, and regulation can turn one weak quarter into a long drawdown.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

My Biggest Investing Regret in 2025 Was Buying This Stock

Canopy Growth is a cautionary reminder to buy businesses, not headlines, especially in hype-driven sectors like cannabis.

Read more »

Yellow caution tape attached to traffic cone
Cannabis Stocks

2 Popular Stocks That Could Wipe Out a $100,000 Nest Egg

Aurora Cannabis (TSX:ACB) is one stock that could wipe out your nest egg.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

Here’s Why I Wouldn’t Touch Canopy Growth Stock With a 10-Foot Pole

Down almost 99% from all-time highs, Canopy Growth is a beaten-down cannabis stock that remains a high-risk investment in 2026.

Read more »

Cannabis business and marijuana industry concept as the shadow of a dollar sign on a group of leaves
Cannabis Stocks

2 Stocks That Could Turn $100,000 Into $0 Faster Than You Think

Canopy Growth and Plug Power are two unprofitable stocks that remain high-risk investments for shareholders in 2026.

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Will Canopy Growth Keep the Losing Streak Going in 2026?

Canopy Growth Corp (TSX:WEED) was one of the market's biggest losers in 2025.

Read more »

Farmer smiles near cannabis crop
Cannabis Stocks

TFSA Investors: An Undervalued Cannabis Stock You Can Buy for $500 Right Now

Down almost 70% from all-time highs, Curaleaf is a TSX cannabis stock that trades at an attractive valuation in December…

Read more »